Decayed Preoperative Serum AGR as a Diagnostic Marker of Poor Prognosis after Radical Surgery of Upper Urinary Tract and Bladder Cancers from a Pooled Analysis of 9,002 Patients

Xiaoyan Wang,1 Guodong Yang,2 Yumeng Chai,1 Zhouye Li,1 Xuanyan Che,1 Yongqiang Wang,3 Liqing Yang,1,3 and Zhongbao Zhou1

1Department of Urology, Beijing Tiantan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Fengtai District, Beijing 100070, China
2Department of Urology, Tengzhou Central People’s Hospital, Tengzhou 277500, China
3Department of Neurology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai 264000, Shandong, China

Correspondence should be addressed to Liqing Yang; 1655345495@qq.com and Zhongbao Zhou; 346894383@qq.com

Received 27 June 2022; Accepted 1 August 2022; Published 5 September 2022

A growing number of studies have regarded the preoperative serum albumin-to-globulin ratio (AGR) as a prognostic indicator of urothelial carcinoma (UC) following radical surgery. However, a pooled analysis of AGR’s effect on UC prognosis was still insufficient. Up to January 2022, a systematic search was conducted using PubMed, Embase, Web of Science, and Cochrane Library. Stata SE software was applied in this study. The reviewers collected the hazard ratio (HR) with 95% confidence interval (CI) for overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), progression-free survival (PFS), and metastasis-free survival (MFS). A total of 9,002 patients from 12 retrospective studies were included in this analysis. The results showed that preoperative serum AGR was significantly associated with the OS (HR = 1.85, 95%CI = 1.43 to 2.39), CSS (HR = 2.38, 95%CI = 1.69 to 3.34), RFS (HR = 1.64, 95%CI = 1.29 to 2.08), PFS (HR = 2.16, 95%CI = 1.43 to 3.27), and MFS (HR = 3.00, 95%CI = 1.63 to 5.53) of patients with UC following radical surgery. Sensitivity analysis indicated the stability of the results. Subgroup analysis revealed that preoperative low AGR was seen as a risk factor for OS (HR = 1.90, 95%CI = 1.34 to 2.69), CSS (HR = 2.13, 95%CI = 1.40 to 3.26), and RFS (HR = 1.60, 95%CI = 1.24 to 2.07) in upper tract urothelial carcinoma (UTUC), but it was only a risk factor for CSS (HR = 2.95, 95%CI = 1.14 to 7.60) in bladder cancer (BC). Besides, preoperative AGR cut – value ≤ 1.4 could not be deemed as a stable prognostic indicator for RFS (HR = 2.07, 95%CI = 0.71 to 6.04) in UC. However, the predictive ability of AGR cut – value > 1.4 was stable. All in all, preoperative low AGR was considered as a risk factor for UC. AGR level can be regarded as a prognostic indicator for OS, CSS, and RFS in UTUC but only for CSS in BC. AGR greater than 1.4 can be a great cut-off value for predicting the prognosis of UC patients with radical operation.

1. Introduction

The most common malignant tumor of urinary system is urothelial carcinoma (UC), which is classified into upper tract urothelial carcinoma (UTUC) and bladder cancer (BC) [1, 2]. UTUC is a very uncommon cancer which contributes up 5% to 10% of all urothelial malignant tumors [3]. The standard therapy for nonmetastatic UTUC is radical nephroureterectomy (RNU) with bladder cuff excision [4].

Nevertheless, the recurrence rate of UTUC after RNU is significant, particularly in individuals with advanced malignancies [5]. BC is one of the tenth most common cancers, and muscle-invasive bladder cancer (MIBC) accounts for about 25% of all BC cases [6]. For individuals with MIBC, the recommended treatment is radical cystectomy (RC) followed by extensive pelvic lymph node dissection [7]. The prognosis of patients with MIBC has greatly improved with advances in surgical technologies and chemotherapeutic medicines in
recent years; although, the five-year survival rate remains much lower than that of patients with other genitourinary tumors [8]. Therefore, the early prediction is critical for guiding later chemotherapy and follow-up regimens.

Multiple postoperative markers, such as clinical stage, pathological grade, and lymphovascular infiltration, are currently utilized to predict prognosis. However, these characteristics are generally examined by pathological assessment, making it difficult to assess clinical outcomes preoperatively [9, 10]. Reliable preoperative predictive indicators are important because individuals at greater risk of tumorigenesis would benefit from preoperative chemotherapy and lymph node resection [11]. Preoperative regular laboratory blood analysis, as one of quickest, most accessible, and least expensive diagnostic testing, has so far been proved to predict the outcomes of UC patients receiving radical surgery [12–14]. For two key aspects of human serum proteins, albumin (ALB) and globulin (GLB) in assessing nutritional quality and predicting disease prognosis have been well documented [15].

Several research have been conducted during last several years on forecasting the outcomes of UC patients by preoperative serum albumin to globulin ratio (AGR); although, it was still debatable. There is an urgent need for clear data establishing the predictive relevance of AGR in UC. The purpose of this pooled analysis was to determine the effect of preoperative AGR on patients with UC following radical surgery.

2. Methods

2.1. Search Strategy and Eligibility. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) guidelines were used to conduct this pooled analysis [16, 17]. The protocol for this study was not published on any public websites. Until Jan 2022, multiple databases including PubMed, Embase, Web of Science, and Cochrane Library were searched. The search keywords were as follows: (“albumin-to-globulin ratio” or “albumin” or “globulin”) and (“urothelial carcinoma” or “upper tract urothelial carcinoma” or “bladder cancer” or “bladder urothelial carcinoma”).

2.2. Study Selection Criteria. The inclusion criteria are as follows: [1] population: patients diagnosed with urinary tract cancers including UTUC or BC had AGR pretreatment of radical surgery; [2] intervention: AGR pretreatment (low); [3] comparator: AGR pretreatment (high); [4] outcomes: prognostic indicators; and [5] study designs: clinical research. Non-English language reports, in vitro studies, case reports, brief reports, conference abstracts/posters, and reviews were all excluded. If there were differences, the team would discuss and solve them. The inclusion criteria and exclusion criteria followed the PICOS principle (Table 1) [18].

2.3. Data Extraction. The extracted data were as follows: publication time, country, patient numbers, study design, tumor type, surgery type, AGR value (high/low), AGR value selection, median follow-up, overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), progression-free survival (PFS), and metastasis-free survival (MFS). We contacted the corresponding authors to obtain more information if some indicators could not be derived from the original manuscript. Hazard ratio (HR) with 95% confidence interval (CI) extracted from multivariate analyses was prioritized. If only Kaplan-Meier curves were available, the relevant data were extracted using Engauge Digitizer 4.1 to calculate HR and 95% CI [19, 20].

2.4. Quality Assessment. This study adopted the Newcastle-Ottawa Scale (NOS) to evaluate the quality of selected studies, including three items: selection (1-4 points), comparability (1-2 points), and exposure (1-3 points), with total scores ranging from 0 (lowest) to 9 (highest) [21]. Studies with seven scores or more would be classified into high-quality and enrolled in the pooled analysis.

2.5. Statistical Analysis. All statistical analyses were performed using Stata E software. The association of preoperative AGR and OS, CSS, RFS, PFS, and MFS was evaluated by combining HR with 95% CI. We used high preoperative AGR as a reference, and HR > 1 indicated a negative impact of low preoperative AGR on UC patients. If HR with 95% CI was reported for high AGR versus low AGR, then HR for low AGR versus high AGR group would be obtained by Kaplan-Meier curves. The $I^2$ statistic was adopted to assess
the heterogeneity among several studies. Heterogeneity in this study was high; so, we adopted the random-effect model to reduce the effect of heterogeneity. Subgroup analysis was used to explore the effect of different classification on clinical outcomes. Sensitivity analysis was performed to assess whether each study significantly affected the pooled HR. \( P < 0.05 \) was considered statistically significant.

3. Results

3.1. Study Characteristics. In the initial search, 356 studies were discovered. Based on the inclusion and exclusion criteria, 344 articles were excluded. Finally, 12 retrospective studies were included in the eventual analysis, including 9,002 UC cases [22–33]. Table 2 summarizes the details of each study. The study screening process was shown in Figure 1. The quality of each study was rated as high quality by NOS tools (Table 3).

3.2. Overall Survival. Ten articles collecting 8,530 UC cases were involved in the research to analyze the relationship of preoperative AGR and OS. The forest plots reflected a HR of 1.85 (95% CI 1.43 to 2.39; \( I^2 = 83.1\% \)). The results revealed that low preoperative AGR was a risk factor for the OS of UC cases after radical operation (Figure 2).

3.3. Cancer-Specific Survival. Nine articles collecting 8,590 UC cases were involved in the research to analyze the relationship of preoperative AGR and CSS. The forest plots reflected a HR of 2.38 (95% CI 1.69 to 3.34; \( I^2 = 87.7\% \)), which revealed that low preoperative AGR was a risk factor for the CSS of UC cases after radical operation (Figure 3).

3.4. Recurrence-Free Survival. Seven articles collecting 8,039 UC cases were involved in the research to analyze the relationship of preoperative AGR and RFS. The forest plots reflected an HR of 1.64 (95% CI 1.29 to 2.08; \( I^2 = 78.5\% \)), which revealed that low preoperative AGR was a risk factor for the RFS of UC cases after radical operation (Figure 4).

3.5. Progression-Free Survival. Two articles collecting 316 UC cases were involved in the research to analyze the relationship of preoperative AGR and PFS. The forest plots reflected an HR of 2.16 and 95% CI of 1.43 to 3.27, which revealed that low preoperative AGR was a risk factor for the PFS of UC cases after radical operation (Figure 4).

3.6. Metastasis-Free Survival. One article collecting 176 UC cases was involved in the research for the relationship of preoperative AGR level and MFS. The forest plots reflected an HR of 3.00 and 95% CI of 1.63 to 5.53. The results revealed

| Study | Study design | Country | Sample size | Tumor | Treatment | AGR value (high/low) | AGR value selection | Outcome | Median follow-up (months; range) |
|-------|--------------|---------|-------------|-------|-----------|---------------------|--------------------|---------|----------------------------------|
| Zhang et al. [28] | Retrospective study | China | 187 | UTUC | Radical nephroureterectomy | 1.45 | ROC | OS; CSS | 78 (32-92) |
| Xu et al. [27] | Retrospective study | China | 620 | UTUC | Radical nephroureterectomy | 1.45 | ROC | OS; CSS; RFS | 50 (28-78) |
| Fukushima et al. [26] | Retrospective study | Japan | 105 | UTUC | Radical nephroureterectomy | 1.24 | ROC | OS | 46 (22-83) |
| Otsuka et al. [25] | Retrospective study | Japan | 124 | UTUC | Radical nephroureterectomy | 1.4 | ROC | OS; CSS; RFS | 55 (28-76) |
| Pradere et al. [24] | Retrospective study | Multicenter | 172 | UTUC | Radical nephroureterectomy | 1.42 | ROC | OS; RFS | 26 (11-56) |
| Omura et al. [23] | Retrospective study | Japan | 179 | UTUC | Radical nephroureterectomy | 1.25 | ROC | OS; CSS | 34 (17-63) |
| Miura et al. [22] | Retrospective study | Multicenter | 2492 | UTUC | Radical nephroureterectomy | 1.4 | ROC | OS; CSS; RFS | 38 (NA) |
| Liu et al. [33] | Retrospective study | China | 296 | BC | Radical cystectomy | 1.6 | ROC | CSS; RFS | 72 (49.75-115.50) |
| Liu et al. [32] | Retrospective study | China | 189 | BC | Radical cystectomy | 1.55 | ROC | OS; CSS; PFS | 38 (1-90) |
| Victor et al. [31] | Retrospective study | Multicenter | 4335 | BC | Radical cystectomy | 1.42 | ROC | OS; CSS; RFS | 31.5 (13.3-72.3) |
| Jeong Seok Oh et al. [30] | Retrospective study | Korea | 176 | BC | Radical cystectomy | 1.32 | ROC | CSS; MFS | 32.4 (0.2-95.3) |
| Zhang et al. [29] | Retrospective study | China | 127 | BC | Radical cystectomy | 1.55 | ROC | OS; PFS | Until March 2018 |

UTUC: upper tract urothelial carcinoma; BC: bladder cancer; ROC: receiver operating curve; OS: overall survival; CSS: cancer-specific survival; RFS: recurrence-free survival; PFS: progression-free survival; MFS: metastasis-free survival; AGR: albumin-to-globulin ratio.
Records identified through database searching \((n = 356)\)

Additional records identified through other sources \((n = 0)\)

Records after duplicates removed \((n = 356)\)

Records screened \((n = 356)\)

Records excluded \((n = 284)\)

Full-text articles assessed for eligibility \((n = 72)\)

Full-text articles excluded, with reasons \((n = 60)\)

Studies included in qualitative synthesis \((n = 12)\)

Studies included in quantitative synthesis (meta-analysis) \((n = 12)\)

Figure 1: The PRISMA of selection process.

Table 3: Quality assessment of the included studies.

| Study                  | Definition adequate | Represent of cases | Selection of controls | Definition of controls | Comparability | Ascertainment of exposure | Exposure | Same method of ascertainment | Nonresponse rate | Score |
|------------------------|---------------------|--------------------|-----------------------|------------------------|---------------|----------------------------|----------|-------------------------------|-----------------|-------|
| Zhang et al. [28]      | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 8     |
| Xu et al. [27]         | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 9     |
| Fukushima et al. [26]  | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 7     |
| Otsuka et al. [25]     | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 7     |
| Pradere et al. [24]    | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 9     |
| Omura et al. [23]      | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 9     |
| Miura et al. [22]      | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 8     |
| Liu et al. [33]        | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 9     |
| Liu et al. [32]        | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 8     |
| Victor et al. [31]     | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 8     |
| Jeong Seok Oh et al. [30] | [ ]             | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 8     |
| Zhang et al. [29]      | [ ]                 | [ ]                | [ ]                   | [ ]                    | [ ]           | [ ]                        | [ ]       | [ ]                           |                 | 8     |
that low preoperative AGR was a risk factor for the MFS of UC cases after radical operation (Figure 4).

3.7. Subgroup Analysis Based on Tumor Type. Of all the included studies, seven studies involved patients with UTUC who underwent RNU, and five studies involved BC patients who underwent RC. The analysis revealed that low preoperative AGR was seen as a risk indicator for OS (HR = 1.90, 95%CI = 1.34 – 2.69), CSS (HR = 2.13, 95%CI = 1.40 – 3.26), and RFS (HR = 1.60, 95%CI = 1.24 – 2.07) in UTUC cases (Figures 5–7). Low preoperative AGR was a risk indicator for CSS (HR = 2.95, 95%CI = 1.14 – 7.60) in BC cases after radical operation but not for OS (HR = 2.19, 95%CI = 0.88 – 5.42) and RFS (HR = 2.03, 95%CI = 0.67 – 6.10) (Figures 5–7).

3.8. Subgroup Analysis Based on AGR Cut Value. Among all the included studies, seven studies reported an optimal cut-off value of AGR greater than 1.4, and five studies reported an optimal cutoff value of AGR less than or equal to 1.4. The analysis revealed that the cut-off value of AGR greater than 1.4 can well predict OS (HR = 1.90, 95%CI = 1.26 – 2.87), CSS (HR = 2.48, 95%CI = 1.37 – 4.47), and RFS (HR = 1.68, 95%CI = 1.20 – 2.36) in UC cases after radical operation (Figures 8–10). The cut-off value of AGR less than or equal to 1.4 can well predict OS (HR = 2.16, 95%CI = 1.14 – 4.10) and CSS (HR = 2.53, 95%CI = 1.29 – 4.96) in UC cases after radical operation but not for RFS (HR = 2.07, 95%CI = 0.71 – 6.04) (Figures 8–10).

3.9. Sensitivity Analysis. Sensitivity analysis was performed to assess whether each study significantly affected the pooled HR. The sensitivity analysis indicated that a single study could not significantly alter the pooled results of OS (Figure 11), CSS (Figure 12), and RFS (Figure 13) in UC cases after radical operation.
4. Discussion

This pooled analysis was conducted to investigate the prognostic value of preoperative AGR in UC cases after radical operation. A total of 9,002 patients from 12 eligible retrospective studies were included [22–33]. The results indicated that preoperative AGR was significantly related with the OS, CSS, RFS, PFS, and MFS of UC patients. Sensitivity analysis showed the stability of these results. Subgroup analysis revealed that a low preoperative AGR was seen as a risk indicator for the OS, CSS, and RFS of UTUC cases, but it was only a risk indicator for the CSS of BC cases. Moreover, the cut-off value of AGR greater than 1.4 can well predict OS, CSS, and RFS in UC cases after radical operation. The cut-off value of AGR less than or equal to 1.4 can well predict OS and CSS in UC cases after radical operation, but not for RFS.

Further study was needed to determine the relationship between decreased AGR and bad prognosis in patients with cancers. Nevertheless, existing data showed that lower diet, or hypoalbuminemia, was a risk factor for some cancers [13, 34]. The primary serum protein constituents are

\begin{table}
\centering
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Study ID} & \textbf{UTUC} & \textbf{BC} \\
\hline
Bo Zhang (2015) & 2.33 (1.42, 3.84) & 2.68 (1.22, 5.85) \\
Hang Xu (2018) & 2.06 (1.59, 2.67) & 4.18 (1.96, 8.94) \\
Hiroshi Fukushima (2018) & 5.12 (1.50, 17.45) & 1.12 (1.02, 1.22) \\
Masafumi Otsuka (2018) & 3.12 (1.47, 6.83) & 4.18 (1.96, 8.94) \\
Benjamin Pradere (2020) & 3.96 (1.65, 10.11) & 2.16 (1.12, 3.92) \\
Noriyoshi Miura (2021) & 1.33 (0.77, 2.31) & 1.20 (1.08, 1.33) \\
Jianye Liu (2016) & 1.31 (1.11, 1.53) & 2.09 (1.12, 3.92) \\
Victor M. Schuettertort (2020) & 3.70 (2.06, 6.67) & 1.18 (1.02, 1.35) \\
Subtotal (I-squared = 87.4%, p < 0.001) & 1.18 (1.02, 1.35) & 1.90 (1.34, 2.69) \\
\hline
\end{tabular}
\caption{Hazard ratios (HR) for OS according to tumor type including UTUC and BC.}
\end{table}

\begin{table}
\centering
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Study ID} & \textbf{RFS} & \textbf{PFS} & \textbf{MFS} \\
\hline
Bo Zhang (2015) & 1.50 (0.20, 11.84) & 2.35 (1.46, 3.80) & 3.00 (1.63, 5.53) \\
Hang Xu (2018) & 1.82 (1.43, 2.31) & 2.09 (1.12, 3.92) & 3.00 (1.63, 5.53) \\
Masafumi Otsuka (2018) & 3.96 (1.65, 10.11) & 1.20 (1.08, 1.33) & 3.00 (1.63, 5.53) \\
Benjamin Pradere (2020) & 1.33 (0.77, 2.31) & 2.09 (1.12, 3.92) & 3.00 (1.63, 5.53) \\
Noriyoshi Miura (2021) & 1.31 (1.11, 1.53) & 1.20 (1.08, 1.33) & 3.00 (1.63, 5.53) \\
Subtotal (I-squared = 78.5%, p < 0.001) & 1.31 (1.11, 1.53) & 1.20 (1.08, 1.33) & 3.00 (1.63, 5.53) \\
\hline
\end{tabular}
\caption{Hazard ratios (HR) for RFS, PFS, and MFS in UC patients after radical operation.}
\end{table}
albumin and globulin, which are usually tested prior to surgery [35]. Albumin is commonly utilized in people with cancer to assess nutritional quality and systemic inflammation [36, 37]. The research has shown that lower serum albumin level was an independent prognostic factor of long-term survival in a variety of cancers [38]. Inflammatory process caused by serum globulins was essential for tumor growth, immune evasion, and spreading [34]. He et al. reported that serum globulins released by cancer tissues enhanced tumor formation, immunosuppressive, and cancer cell metastasis [34]. Furthermore, Laursen et al. discovered that serum albumin might modulate the capabilities of autocrine growth regulatory factors, which would really affect tumor growth [39]. Multiple studies have confirmed that serum albumin could reliably predict poorer oncologic results in UTUC patients [14, 38].

Therefore, a lower AGR can more sensitively estimate the extent of poor nutritional status and cancer growth than that of any parameter separately and may contribute as a directly important diagnostic indicator [22].

| Study ID          | Hazard ratio (95% CI) | % weight |
|-------------------|-----------------------|----------|
| Bo Zhang (2015)   | 1.82 (1.02, 3.26)     | 19.27    |
| Hang Xu (2018)    | 2.33 (1.73, 3.16)     | 26.11    |
| Masafumi Otsuka (2018) | 5.69 (2.13, 17.22) | 10.65    |
| Shota Omura (2020) | 2.81 (1.34, 6.10)   | 15.36    |
| Noriyoshi Miura (2021) | 1.31 (1.10, 1.56) | 28.61    |
| subtotal (I-squared = 78.9%, p = 0.001) | 2.13 (1.40, 3.26) | 100.00   |

| BC                | Hazard ratio (95% CI) | % weight |
|-------------------|-----------------------|----------|
| Jianye Liu (2016) | 7.03 (3.69, 13.40)    | 24.72    |
| Zhenhua Liu (2017) | 3.50 (1.50, 8.13)    | 22.85    |
| Victor M. Schuettfort (2020) | 1.18 (1.06, 1.33) | 27.81    |
| Jeong Seok Oh (2021) | 2.96 (1.54, 5.70) | 24.62    |
| subtotal (I-squared = 92.6%, p < 0.001) | 2.95 (1.14, 7.60) | 100.00   |

Note: Weights are from random effects analysis

---

**Figure 6:** Forest plot of hazard ratios (HR) for cancer-specific survival (CSS) according to tumor type including UTUC and BC.

---

| Study ID          | Hazard ratio (95% CI) | % weight |
|-------------------|-----------------------|----------|
| Bo Zhang (2015)   | 1.58 (0.91, 2.73)     | 14.22    |
| Hang Xu (2018)    | 1.82 (1.43, 2.31)     | 29.91    |
| Masafumi Otsuka (2018) | 3.96 (1.65, 10.11) | 6.72     |
| Benjamin Pradere (2020) | 1.33 (0.77, 2.31) | 14.22    |
| Noriyoshi Miura (2021) | 1.31 (1.11, 1.53) | 34.92    |
| subtotal (I-squared = 59.2%, p = 0.044) | 1.60 (1.24, 2.07) | 100.00   |

| BC                | Hazard ratio (95% CI) | % weight |
|-------------------|-----------------------|----------|
| Jianye Liu (2016) | 3.70 (2.06, 6.67)     | 46.57    |
| Victor M. Schuettfort (2020) | 1.20 (1.08, 1.33) | 53.43    |
| subtotal (I-squared = 92.7%, p < 0.001) | 2.03 (0.67, 6.10) | 100.00   |

Note: Weight are from random effects analysis

---

**Figure 7:** Forest plot of hazard ratios (HR) for recurrence-free survival (RFS) according to tumor type including UTUC and BC.
systemic inflammation indicators, such as neutrophil-to-lymphocyte ratio and lymphocyte-to-monocyte ratio, have already been created and widely studied in the area of cancer, depending on a similar principle as AGR [40, 41]. Many studies have been performed in the last ten years to investigate the efficacy and specificity of preoperative AGR as a predicted prognostic marker for various malignancies [42]. Lower AGR was a potential risk factor for incidence of cancer and disease deaths in a normal monitoring community in both the short and long terms [43]. According to a meta-analysis of preoperative AGR and clinical malignancies, lower preoperative AGR was associated with the poorer OS, PFS, and disease-free survival [42]. Notably, the predictive effect of AGR remained independent of AGR cut-off values and cancer type, despite AGR cut-off ratios varied, varying between 0.9 and 1.93 for various malignancies.

| Study ID | Hazard ratio (95% CI) | % weight |
|----------|-----------------------|----------|
| 1. AGR > 1.4 | | |
| Bo Zhang (2015) | 2.33 (1.42, 3.84) | 16.82 |
| Hang Xu (2018) | 2.06 (1.59, 2.67) | 20.44 |
| Benjamin Pradere (2020) | 1.16 (0.63, 1.96) | 15.67 |
| Zhenhua Liu (2017) | 2.68 (1.22, 5.85) | 12.36 |
| Victor M. Schuettfert (2020) | 1.12 (1.02, 1.22) | 22.00 |
| Wentao Zhang (2021) | 4.18 (1.96, 8.94) | 12.71 |
| Subtotal (I-squared = 87.3%, p < 0.001) | 1.90 (1.26, 2.87) | 100.00 |

| Study ID | Hazard ratio (95% CI) | % weight |
|----------|-----------------------|----------|
| 2. AGR < 1.4 | | |
| Hiroshi Fukushima (2018) | 5.12 (1.50, 17.45) | 15.40 |
| Masafumi Otsuka (2018) | 3.12 (1.47, 6.83) | 23.44 |
| Shota Omura (2020) | 2.09 (1.12, 3.92) | 26.42 |
| Noriyoshi Miura (2021) | 1.18 (1.02, 1.35) | 34.75 |
| Subtotal (I-squared = 78.1%, p = 0.003) | 2.16 (1.14, 4.10) | 100.00 |

Note: Weights are from random effects analysis.

Figure 8: Forest plot of hazard ratios (HR) for overall survival (OS) according to AGR cut-value including ≤1.4 and >1.4.

| Study ID | Hazard ratio (95% CI) | % weight |
|----------|-----------------------|----------|
| 1. AGR > 1.4 | | |
| Bo Zhang (2015) | 1.82 (1.20, 3.26) | 19.37 |
| Hang Xu (2018) | 2.33 (1.73, 3.16) | 22.44 |
| Jianye Liu (2016) | 7.03 (3.69, 13.40) | 18.54 |
| Zhenhua Liu (2017) | 3.50 (1.50, 8.13) | 16.01 |
| Victor M.Schuettfort (2020) | 1.18 (1.06, 1.33) | 23.63 |
| Subtotal (I-squared = 91.8%, p < 0.001) | 2.48 (1.37, 4.47) | 100.00 |

| Study ID | Hazard ratio (95% CI) | % weight |
|----------|-----------------------|----------|
| 2. AGR ≤ 1.4 | | |
| Masafumi Otsuka (2018) | 5.69 (2.13, 17.22) | 18.49 |
| Shota Omura (2020) | 2.81 (1.34, 6.10) | 23.47 |
| Noriyoshi Miura (2021) | 1.31 (1.10, 1.56) | 32.67 |
| Jeong Seok Oh (2021) | 2.96 (1.54, 5.70) | 25.37 |
| Subtotal (I-squared = 80.4%, p = 0.0002) | 2.53 (1.29, 4.96) | 100.00 |

Note: weights are from random effects analysis.

Figure 9: Forest plot of hazard ratios (HR) for cancer-specific survival (CSS) according to AGR cut-value including ≤1.4 and >1.4.
The AGR cut-off ratio among UTUC subjects, on the other hand, was nearly consistent, varying between 1.4 and 1.45 [42].

This study reported that perioperative AGR can forecast poorer RFS, CSS, and OS before undergoing radical surgery. Despite growing evidence to the contrary, neoadjuvant chemotherapy was the acknowledged common treatment for MIBC but not for UTUC [44]. Although more advances in contemporary imaging methods such as computed tomography and magnetic resonance imaging, accurate staging of UTUC preoperatively was challenging. Because of the small size of tissue samples, preoperative UTUC assessment with histology was especially difficult [45]. Since difficulties in preoperative UTUC staging and histology classification, some individuals may be overtreated while others managed with RNU monotherapy may be undertreated [46]. Considering the loss of renal function accompanied with nephrectomy, a neoadjuvant treatment was an appealing alternative for individuals who were probably to

| Study ID | Hazard ratio (95% CI) | % weight |
|----------|----------------------|----------|
| AGR > 1.4 | | |
| Bo Zhang (2015) | 1.58 (0.91, 2.73) | 16.23 |
| Hang Xu (2018) | 1.82 (1.43, 2.31) | 24.74 |
| Benjamin Pradere (2020) | 1.33 (0.77, 2.31) | 16.23 |
| Jianye Liu (2016) | 3.70 (2.06, 6.67) | 15.29 |
| Victor M. Schuettfort (2020) | 1.20 (1.08, 1.33) | 27.50 |
| Subtotal (I-squared = 82.1%, p < 0.001) | 1.68 (1.20, 2.36) | 100.00 |
| AGR ≤ 1.4 | | |
| Masafumi Otsuka (2018) | 3.98 (1.65, 10.11) | 41.54 |
| Noriyoshi Miura (2021) | 1.31 (1.11, 1.53) | 58.46 |
| Subtotal (I-squared = 82.0%, p = 0.018) | 2.07 (0.71, 6.04) | 100.00 |

Note: Weights are from random effects analysis

Figure 10: Forest plot of hazard ratios (HR) for recurrence-free survival (RFS) according to AGR cut-value including ≤1.4 and >1.4.

Meta-analysis estimated, given named study is omitted

Figure 11: Sensitivity analysis for overall survival (OS) in UC patients.
need it and benefit [47]. As a result, reliable preoperative indicators which can be capable of identifying patients for neoadjuvant therapy were required [48]. Preoperative AGR may be a valuable indicator for decision support in individuals experiencing preoperative systemic treatment guidance, whereas the pooled analysis demonstrated a high connection between AGR and UC prognosis, and some limitations should be noted. Firstly, all the research used retrospective methods, which raised the possibility of bias. Secondly, dietary inadequacies, illnesses, drugs, and lifestyle can influence blood-based indicators, resulting in a bias. Thirdly, while the random-effect model took into account the variability of studies, the results must be carefully considered when using it. Finally, the majority of patients in our research came from a specific region of Asia, which may make it difficult to generalize the results.

5. Conclusions

Preoperative low AGR was considered as a risk factor for UC. AGR level can be regarded as a prognostic indicator for OS, CSS, and RFS in UTUC but only for CSS in BC. AGR greater than 1.4 can be a great cut-off value for predicting the prognosis of UC patients with radical operation.

Data Availability

The datasets used and/or analyzed during the current study available from the corresponding authors on reasonable request.
Conflicts of Interest

The authors have no conflict of interest to declare.

Authors’ Contributions

All authors constructed this study. Xiaoyan Wang, Guodong Yang, Yumeng Chai, and Zhouyue Li performed the data analysis, figures plotted, and writing. Zhongbao Zhou, Yongqiang Wang, Liqing Yang, and Xuanyan Che were responsible for the critical reading of the manuscript. All authors contributed to the article and approved the submitted version. Xiaoyan Wang and Guodong Yang contributed equally to this work as co-first authors. Zhongbao Zhou was the first corresponding author of this article, and Liqing Yang was the co-corresponding author of this article.

Acknowledgments

This work was supported by the Beijing Municipal Administration of Hospitals’ Ascent Plan (Code: DFL20190502), Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (Code: ZYLYX201820) and Shandong Provincial Natural Science Foundation (Code: ZR2021MH186).

References

[1] F. Liedberg, S. Kjellström, A. K. Lind et al., “Swedish National Guidelines on urothelial carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma,” Scandinavian journal of urology, vol. 56, no. 2, pp. 137–146, 2022.

[2] R. Cathomas, A. Lorch, H. M. Bruins et al., “The 2021 updated European Association of Urology Guidelines on metastatic urothelial carcinoma,” European Urology, vol. 81, no. 1, pp. 95–103, 2022.

[3] M. Rouprêt, M. Babjuk, M. Burger et al., “European Association of Urology Guidelines on upper urinary tract urothelial carcinoma: 2020 update,” European Urology, vol. 79, no. 1, pp. 62–79, 2021.

[4] V. Margulis, S. F. Shariat, S. F. Matin et al., “Outcomes of radical nephroureterectomy: a series from the upper tract urothelial carcinoma collaboration,” Cancer, vol. 115, no. 6, pp. 1224–1233, 2009.

[5] M. Remzi, A. Haitel, V. Margulis et al., “Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients,” BJU International, vol. 103, no. 3, pp. 307–311, 2009.

[6] H. Sung, J. Ferlay, R. L. Siegel et al., “Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries,” CA: a cancer journal for clinicians, vol. 71, no. 3, pp. 209–249, 2021.

[7] J. A. Witjes, M. Babjuk, J. Bellmunt et al., “EAU-ESMO Consensus statements on the management of advanced and variant bladder cancer—an international collaborative multisponsorship effort!: under the auspices of the EAU-ESMO Guidelines Committee,” European Urology, vol. 77, no. 2, pp. 223–250, 2020.

[8] S. Hong, Y. J. Won, Y. R. Park et al., “Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2017,” Cancer research and treatment: official journal of Korean Cancer Association, vol. 52, no. 2, pp. 335–350, 2020.

[9] I. H. Chen, C. H. Chang, C. P. Huang et al., “Factors Predicting Oncological Outcomes of Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma in Taiwan,” Frontiers in Oncology, vol. 11, 2022.

[10] S. Venkat, A. I. Khan, P. J. Lewicki, L. Borregales, and D. S. Scherr, “Novel nomograms to predict muscle invasion and lymph node metastasis in upper tract urothelial carcinoma,” Urologic Oncology, vol. 40, no. 3, p. 108.e11–e17, 2022.

[11] M. Roscigno, M. Brausi, A. Heidenreich et al., “Lymphadenectomy at the time of nephroureterectomy for upper tract urothelial cancer,” European Urology, vol. 60, no. 4, pp. 776–783, 2011.

[12] M. D. Vartolomei, S. Kimura, M. Ferro et al., “Is neutrophil-to-lymphocytes ratio a clinical relevant preoperative biomarker in upper tract urothelial carcinoma? A meta-analysis of 4385 patients,” World Journal of Urology, vol. 36, no. 7, pp. 1019–1029, 2018.

[13] J. Huang, Y. Yuan, Y. Wang et al., “Preoperative prognostic nutritional index is a significant predictor of survival in patients with localized upper tract urothelial carcinoma after radical nephroureterectomy,” Urologic Oncology, vol. 35, no. 12, p. 671.e1–e9, 2017.

[14] J. H. Ku, M. Kim, W. S. Choi, C. Kwak, and H. H. Kim, “Preoperative serum albumin as a prognostic factor in patients with upper urinary tract urothelial carcinoma,” International braz j urol. official journal of the Brazilian Society of Urology, vol. 40, no. 6, pp. 753–762, 2014.

[15] Z. Chen, Y. Shao, H. Yao et al., “Preoperative albumin to globulin ratio predicts survival in clear cell renal cell carcinoma patients,” Oncotarget, vol. 8, no. 29, pp. 48291–48302, 2017.

[16] M. J. Page, J. E. McKenzie, P. M. Bossuyt et al., “The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews,” International Journal of Surgery (London, England), vol. 88, p. 105906, 2021.

[17] B. J. Shea, B. C. Reeves, G. Wells et al., “AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both,” BMJ (Clinical research ed), vol. 358, 2017.

[18] M. Amir-Behgadami and A. Janati, “Population, intervention, comparison, outcomes and study (PICOS) design as a framework to formulate eligibility criteria in systematic reviews,” Emergency medicine journal: EMJ, vol. 37, no. 6, p. 387, 2020.

[19] P. R. Williamson, C. T. Smith, J. L. Hutton, and A. G. Marson, “Aggregate data meta-analysis with time-to-event outcomes,” Statistics in medicine, vol. 21, no. 22, pp. 3337–3351, 2002.

[20] M. K. Parmar, V. Torri, and L. Steward, “Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints,” Statistics in medicine, vol. 17, no. 24, pp. 2815–2834, 1998.

[21] G. Guyatt, A. D. Oxman, E. A. Akl et al., “GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables,” Journal of Clinical Epidemiology, vol. 64, no. 4, pp. 383–394, 2011.

[22] N. Miura, K. Mori, E. Laukhitana et al., “Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration,” Japanese Journal of Clinical Oncology, vol. 51, no. 7, pp. 1149–1157, 2021.
[23] S. Omura, S. Taguchi, S. Miyagawa et al., "Prognostic significance of the albumin-to-globulin ratio for upper tract urothelial carcinoma," BMC urology, vol. 20, no. 1, p. 133, 2020.

[24] B. Pradere, D. Andrea, V. M. Schuettfort et al., "Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma," World journal of urology, vol. 39, no. 7, pp. 2567–2577, 2021.

[25] M. Otsuka, T. Kamasako, T. Uemura et al., "Prognostic role of the preoperative serum albumin: globulin ratio after radical nephroureterectomy for upper tract urothelial carcinoma," International journal of urology: official journal of the Japanese Urological Association, vol. 25, no. 10, pp. 871–878, 2018.

[26] H. Fukushima, M. Kobayashi, K. Kawano, and S. Morimoto, "Prognostic value of albumin/globulin ratio in patients with upper tract urothelial carcinoma patients treated with radical nephroureterectomy," Anticancer research, vol. 38, no. 4, pp. 2329–2334, 2018.

[27] H. Xu, P. Tan, J. Ai et al., "Prognostic impact of preoperative albumin-globulin ratio on oncologic outcomes in upper tract urothelial carcinoma treated with radical nephroureterectomy," Clinical Genitourinary Cancer, vol. 16, no. 5, pp. e1059–e1068, 2018.

[28] B. Zhang, W. Yu, L. Q. Zhou et al., "Prognostic significance of preoperative albumin-globulin ratio in patients with upper tract urothelial carcinoma," PloS one, vol. 10, no. 12, article e0144961, 2015.

[29] W. Zhang, F. Yang, A. Kadier et al., "Development of nomograms related to inflammatory biomarkers to estimate the prognosis of bladder cancer after radical cystectomy," Annals of translational medicine, vol. 9, no. 18, p. 1440, 2021.

[30] J. S. Oh, D. J. Park, K. H. Byeon et al., "Decrease of Preoperative Serum Albumin-to-Globulin Ratio as a Prognostic Indicator after Radical Cystectomy in Patients with Urothelial Bladder Cancer," Urology Journal, vol. 18, no. 1, pp. 66–73, 2021.

[31] V. M. Schuettfort, D. D’Andrea, F. Quhal et al., "Impact of preoperative serum albumin-globulin ratio on disease outcome after radical cystectomy for urothelial carcinoma of the bladder," Urologic Oncology, vol. 39, no. 4, pp. 235.e5–235.e14, 2021.

[32] Z. Liu, H. Huang, S. Li et al., "The prognostic value of preoperative serum albumin-globulin ratio for high-grade bladder urothelial carcinoma treated with radical cystectomy: a propensity score-matched analysis," Journal of Cancer Research and Therapeutics, vol. 13, no. 5, pp. 837–843, 2017.

[33] J. Liu, Y. Dai, F. Zhou et al., "The prognostic role of preoperative serum albumin/globulin ratio in patients with bladder urothelial carcinoma undergoing radical cystectomy," Urologic Oncology, vol. 34, no. 11, p. 484.e1–e8, 2016.

[34] J. He, H. Pan, W. Liang et al., "Prognostic effect of albumin-to-globulin ratio in patients with solid tumors: a systematic review and meta-analysis," Journal of Cancer, vol. 8, no. 19, pp. 4002–4010, 2017.

[35] B. N. Azab, V. R. Bhatt, S. Vonfrolio et al., "Value of the pretreatment albumin to globulin ratio in predicting long-term mortality in breast cancer patients," American Journal of Surgery, vol. 206, no. 5, pp. 764–770, 2013.

[36] J. S. Falconer, K. C. Fearon, J. A. Ross et al., "Acute-phase protein response and survival duration of patients with pancreatic cancer," Cancer, vol. 75, no. 8, pp. 2077–2082, 1995.

[37] D. C. McMillan, W. S. Watson, P. O’Gorman, T. Preston, H. R. Scott, and C. S. Mc Ardle, "Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss," Nutrition and Cancer, vol. 39, no. 2, pp. 210–213, 2001.

[38] D. Gupta and C. G. Lis, "Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature," Nutrition journal, vol. 9, p. 69, 2010.

[39] I. Laursen, P. Briand, and A. E. Lykkesfeldt, "Serum albumin as a modulator on growth of the human breast cancer cell line, MCF-7," Anticancer research, vol. 10, no. 2a, pp. 343–351, 1990.

[40] T. Azuma, Y. Matayoshi, K. Odani et al., "Preoperative neutrophil-lymphocyte ratio as an independent prognostic marker for patients with upper urinary tract urothelial carcinoma," Clinical Genitourinary Cancer, vol. 11, no. 3, pp. 337–341, 2013.

[41] F. Cantillo, G. I. Russo, M. D. Vartolomei et al., "Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High- risk Non-muscle-invasive Urothe|lial Bladder Cancer," European urology oncology, vol. 1, no. 5, pp. 403–410, 2018.

[42] G. Y. Lv, L. An, X. D. Sun, Y. L. Hu, and D. W. Sun, "Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers: a meta-analysis," Clinica chimica acta: international journal of clinical chemistry, vol. 476, pp. 81–91, 2018.

[43] B. Suh, S. Park, D. W. Shin et al., "Low albumin-to-globulin ratio associated with cancer incidence and mortality in generally healthy adults," Annals of Oncology, vol. 25, no. 11, pp. 2260–2266, 2014.

[44] B. Foerster, M. Abufaraj, F. Petros et al., "Efficacy of preoperative chemotherapy for high risk upper tract urothelial carcinoma," The Journal of Urology, vol. 203, no. 6, pp. 1101–1108, 2020.

[45] S. H. Yu, Y. H. Hur, E. C. Hwang et al., "Does multidetector computed tomographic urography (MDCTU) T staging classification correspond with pathologic T staging in upper tract urothelial carcinoma?", International Urology and Nephrology, vol. 53, no. 1, pp. 69–75, 2021.

[46] S. Chitale, R. Mbbaka, S. Irving, and N. Burgess, "Nephroureterectomy for transitional cell carcinoma--the value of preoperative histology," "The Annals of The Royal College of Surgeons of England", vol. 90, no. 1, pp. 45–50, 2008.

[47] S. Kobayashi, M. Ito, K. Takemura, H. Suzuki, I. Yonese, and C. S. McArdle, "Nephroureterectomy for transitional cell carcinoma--the value of preoperative histology," "The Annals of The Royal College of Surgeons of England", vol. 90, no. 1, pp. 45–50, 2008.

[48] S. Kobayashi, M. Ito, K. Takemura, H. Suzuki, I. Yonese, and F. Koga, "Preoperative models incorporating the systemic immune-inflammation index for predicting prognosis and muscle invasion in patients with non-metastatic upper tract urothelial carcinoma," International Journal of Clinical Oncology, vol. 27, no. 3, pp. 574–584, 2022.

[49] K. Bansalshah, F. Montorsi, and S. F. Shariat, "Challenges of cancer biomarker profiling," European Urology, vol. 52, no. 6, pp. 1601–1609, 2007.